Quantifying slfn11 protein for optimal cancer therapy

A treatment plan, protein technology, applied in chemical instruments and methods, biochemical equipment and methods, labels used in chemical analysis, etc., can solve the problem of no effective standardization method for measuring SLFN11 protein and so on

Inactive Publication Date: 2020-03-17
NANTOMICS LLC +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no standardized method for efficiently measuring SLFN11 protein in patient tumor cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quantifying slfn11 protein for optimal cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0032] Example: Determination of the predictive value of SLFN11 protein expression in a population of lung cancer patients treated with combination therapy comprising paclitaxel plus platinum-based drugs

[0033] Tumor expression of SLFN11 was measured using mass spectrometry to quantify SLFN11 protein in preserved samples of early-stage lung cancer patients treated with paclitaxel plus platinum (TP). The expression level of SLFN11 is related to the survival rate of patients.

[0034] METHODS: Preserved formalin-fixed, paraffin-embedded tissue sections were obtained from patients with different types of lung cancer treated with paclitaxel plus platinum-based drugs (n=594). A certified pathologist marked the tumor area, which was microdissected and the tissue lysed using the Liquid Tissue protocol and reagents (Expression Pathology, Inc., Rockville, MD). In each liquefied tumor sample, 60 protein biomarkers including SLFN11 were quantified by selected reaction monitoring mass ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods are provided for identifying whether a tumor, and especially a lung tumor, will be responsive to treatment with a therapeutic regimen that contains a platinum-based agent such as cisplatin andoptionally contains a taxane. A specific Schlafen family member 11 (SLFN11) fragment peptide is precisely detected and quantitated by spectrometry directly in lung cancer cells collected from lung tumor tissue obtained from a cancer patient. Comparison to reference levels determines if the cancer patient will respond positively or negatively to treatment with the chemotherapeutic agents taxane plus a platinum-based agent such as cisplatin.

Description

[0001] This application claims priority to U.S. Provisional Application No. 62 / 522,670, entitled "Quantification of SLFN11 Protein for Optimizing Cancer Treatment Regimen," filed June 20, 2017, the contents of which are incorporated herein by reference in their entirety . technical field [0002] The present invention provides improved methods for treating cancer patients. Tumor tissue from the patient is analyzed and the results of the analysis are used to select an improved or optimized treatment regimen to administer to the patient. Background technique [0003] Currently, there are no approved predictive biomarkers for cancer patients treated with standard chemotherapy. The Schlafen family member 11 (SLFN11 ) protein has been widely reported to be required for sensitivity to DNA damaging chemotherapeutic agents. Exogenously mediated inhibition of SLFN11 is associated with poor response to platinum-based agents in ovarian and lung cancer patients. Additionally, preclin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/243A61P35/00B01D59/44C12Q1/37G01N33/00G01N33/574G01N33/566
CPCA61K45/06A61P35/00A61K33/243G01N33/57423G01N2800/52A61K2300/00A61K31/337G01N33/6848G01N33/6893G01N2458/15C12Q1/37C12Q1/6886
Inventor 法比奥拉·切基S·施瓦兹托德·哈姆布拉夫C·M·鲁丁J·T·普瓦里耶
Owner NANTOMICS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap